The impact of pediatric interventional cardiology has never been stronger, nor the need for organized, high-quality training greater, says Frank F. Ing, M.D., FSCAI, who delivered the annual Mullins Lecture at the Society for Cardiovascular Angiography and Interventions (SCAI) 2013 Scientific Sessions. He made the case that advances in technology and growth in the profession mean that now is the time to take training to the next level.


May 13, 2013 — Boston Scientific reports that the four-year follow-up data from the PROTECT AF clinical trial demonstrated the Watchman left atrial appendage (LAA) closure device was statistically superior to warfarin for preventing cardiovascular death, all-cause stroke and systemic embolization.


Biosense Webster Inc. announced the first patient has been enrolled in the reMARQable clinical study. ReMARQable will assess the safety and efficacy of the use of the nMARQ Pulmonary Vein Isolation System to treat paroxysmal atrial fibrillation. Atrial fibrillation (Afib) is a heart rhythm disorder that affects approximately 20 million people worldwide.

 

GE Healthcare Innova EPVision 2.0, an application that combines information from electrophysiology (EP) recording and live fluoroscopy, and Dose Blueprint, a comprehensive dose management strategy helping clinicians achieve in particular 50 percent dose reduction on Innova IGS single plane angiography systems compared to previous releases.

The Population Health Research Institute (PHRI) has conducted a further independent analysis of data received from ongoing prospective registries that monitor the performance of the St. Jude Medical Durata and Riata ST Optim implantable cardioverter defibrillator (ICD) leads.

Boston Scientific has received CE Mark approval for the Rhythmia Mapping System, a 3-D mapping and navigation solution for use in cardiac catheter ablations and other electrophysiology (EP) procedures to treat a variety of conditions in which the heart beats abnormally.  Some of those conditions include atrial flutter, atrial fibrillation and ventricular tachycardia.  Boston Scientific is offering the Rhythmia Mapping System with the company's 64 electrode IntellaMap Orion Mapping Catheter, which has also received CE Mark approval.  The combination, part of the 2012 Rhythmia Medical acquisition, is designed to provide electrophysiologists with accurate, high-resolution electro-anatomical maps. 

Subscribe Now